AI assistant
IMPEDIMED LIMITED — Capital/Financing Update 2019
Jul 25, 2019
65135_rns_2019-07-25_c6e03d95-906c-4d6a-b7d8-1de5e4d7713d.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [230 x 54] intentionally omitted <==
26 July 2019
ASX ANNOUNCEMENT
CHANGE IN EXERCISE PRICE OF OPTIONS
Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD) ( ImpediMed or the Company ), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announced a 1-for-3 fully underwritten, pro-rata, non-renounceable entitlement offer of approximately 126.6 million shares in the Company to raise approximately $13.9 million, on 27 June 2019 ( Entitlement Offer ).
In accordance with the rules of the Company’s 2014 Employee Incentive Plan approved by the board on 18 September 2014 ( Plan ) and ASX Listing Rules 3.11.2 and 6.22, the Company advises that, as a consequence of the Entitlement Offer, the exercise price of options over unissued shares in the Company outstanding under the Plan will change on 2 August 2019 as set out in the table below.
| Options | Current exercise price (US$) | New exercise price (US$) |
|---|---|---|
| 132,000 | 0.6900 | 0.6883 |
| 37,771 | 0.8700 | 0.8683 |
| 5,345,000 | 0.6900 | 0.6883 |
| 1,446,500 | 0.8700 | 0.8683 |
| 200,000 | 1.0300 | 1.0283 |
| 100,000 | 1.0500 | 1.0483 |
| 375,000 | 0.8900 | 0.8883 |
| 200,000 | 1.3200 | 1.3183 |
| 821,000 | 1.6600 | 1.6583 |
| 590,500 | 1.4700 | 1.4683 |
| 335,000 | 1.4600 | 1.4583 |
| 872,000 | 1.4600 | 1.4583 |
| 120,000 | 0.7400 | 0.7383 |
| 262,500 | 0.6400 | 0.6383 |
| 5,575,000 | 0.8150 | 0.8133 |
| 306,000 | 0.6800 | 0.6783 |
| 578,000 | 0.5200 | 0.5183 |
| 70,000 | 0.2300 | 0.2283 |
| 75,000 | 0.2300 | 0.2283 |
| 100,000 | 0.1350 | 0.1333 |
| 533,000 | 0.1350 | 0.1333 |
Contact details
Richard Carreon Managing Director & CEO
Media Contact:
Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: [email protected]
About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.
ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure and lymphoedema, sold in select markets globally.
For more information, visit www.impedimed.com.